Allergan And Medicis/Ipsen Battle Over Marketing Advantage Of REMS
FDA's decision to require a Risk Evaluation and Mitigation Strategy for botulinum toxin products has opened up a marketing battle between Allergan's long-standing Botox and Ipsen/Medicis' the new-to-the-block Dysport
You may also be interested in...
A Nov. 14 advisory committee gave near-unanimous support for Vanda’s sleep disorder drug on questions about its indication, endpoints, efficacy and safety.
Safety efforts designed to discourage interchanging products will benefit the market leader.
Advocates for patients with rare diseases are urging Congress to build in special considerations for treatments for rare diseases in several key provisions of health care reform